DeepMed Research

ASTELLAS PHARMA EUROPE B.V.

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Completed

Conditions: Prostate Cancer

Interventions: Drug: Depo-Eligard®

First Posted Date: 2013-02-15

Last Posted Date: 2014-01-13

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 259

Registration Number: NCT01793077

Locations: 🇧🇪
Site: 5, Antwerpen, Antwerp, Belgium
🇧🇪
Site: 8, Antwerpen, Antwerp, Belgium
🇧🇪
Site: 9, Antwerpen, Antwerp, Belgium

and more 20 locations

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: ASP1707
Drug: Placebo
Drug: Leuprorelin acetate

First Posted Date: 2013-01-14

Last Posted Date: 2024-10-23

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 912

Registration Number: NCT01767090

Locations: 🇵🇱
Site: 1505, Bialystok, Poland
🇵🇱
Site: 1508, Lublin, Poland
🇵🇱
Site: 1509, Warsaw, Poland

and more 82 locations

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

Completed

Conditions: Systemic Fungal Infections

Interventions: Drug: Parenteral micafungin application
Drug: Other parenteral antifungal drugs

First Posted Date: 2012-09-18

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 40110

Registration Number: NCT01686607

Locations: 🇺🇸
Site US4, Baltimore, Maryland, United States
🇺🇸
Site US2, Boston, Massachusetts, United States
🇺🇸
Site US1, Pittsburgh, Pennsylvania, United States

and more 3 locations

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YM178 OCAS
Drug: Digoxin

First Posted Date: 2012-08-14

Last Posted Date: 2015-09-01

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 25

Registration Number: NCT01663961

Locations: 🇫🇷
SGS Aster, Paris, France

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Phase 1

Completed

Conditions: Pharmacokinetics
Healthy Male Subjects

Interventions: Drug: YM150

First Posted Date: 2012-08-06

Last Posted Date: 2013-06-26

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 6

Registration Number: NCT01657981

Locations: 🇳🇱
PRA International EDS NL, Zuidlaren, Netherlands

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Phase 1

Completed

Conditions: Pharmacokinetics
Pharmacodynamics
Healthy Subjects
Caucasian
Japanese

Interventions: Drug: YM150
Drug: Placebo

First Posted Date: 2012-08-01

Last Posted Date: 2013-06-26

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 82

Registration Number: NCT01655056

Locations: 🇩🇪
FOCUS Clinical Drug Development GmbH, Neuss, Germany

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

Phase 3

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Solifenacin succinate suspension

First Posted Date: 2012-08-01

Last Posted Date: 2024-11-13

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 148

Registration Number: NCT01655069

Locations: 🇧🇪
Site: 3209, Antwerp, Belgium
🇺🇸
Site: 1006, Shreveport, Louisiana, United States
🇵🇭
Site: 6301, Quezon City, Philippines

and more 36 locations

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Phase 1

Completed

Conditions: Metabolic Processes

Interventions: Drug: 14C-labeled YM178

First Posted Date: 2012-07-27

Last Posted Date: 2013-09-05

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 4

Registration Number: NCT01651312

Locations: 🇳🇱
Pharma Bio-Research Group B.V., Zuidlaren, Netherlands

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Phase 1

Completed

Conditions: Pharmacokinetics of YM178
Healthy Subjects

Interventions: Drug: YM178 modified release (OCAS)
Drug: YM178 immediate release (IR)

First Posted Date: 2012-07-20

Last Posted Date: 2013-07-02

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 34

Registration Number: NCT01646294

Locations: 🇳🇱
Pharma Bio-Research B.V., Zuidlaren, Netherlands

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)

Phase 2

Completed

Conditions: Cystitis, Interstitial
Urinary Bladder Disease
Pain
Urologic Diseases

Interventions: Drug: ASP3652
Drug: Placebo

First Posted Date: 2012-06-07

Last Posted Date: 2024-11-05

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 287

Registration Number: NCT01613586

Locations: 🇧🇪
Site: 5101, Antwerp, Belgium
🇨🇿
Site: 5201, Uherske Hradiste, Czechia
🇨🇿
Site: 5209, Plzen, Czechia

and more 57 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy